Entering text into the input field will update the search result below

Omeros Corp (OMER) CEO Greg Demopulos on Q4 2020 Results - Earnings Call Transcript

Mar. 01, 2021 9:35 PM ETOmeros Corporation (OMER)10 Comments
SA Transcripts profile picture
SA Transcripts

Omeros Corp (NASDAQ:OMER) Q4 2020 Earnings Conference Call March 1, 2020 4:30 PM ET

Company Participants

Jennifer Williams - IR

Greg Demopulos - Co-Founder, Chairman, CEO & President

Michael Jacobsen - CAO, VP, Finance & Treasurer

Daniel Kirby - Chief Commercial Officer, VP & Head, Commercial

Steve Whitaker - VP, Clinical Development

Conference Call Participants

Steve Brozak - WBB Securities

Alice Nettleton - UBS

Raghuram Selvaraju - H.C. Wainwright & Co.

Serge Belanger - Needham & Company

Brandon Folkes - Cantor Fitzgerald & Co.


Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time all participants are in a listen-only mode. After the company's remarks, we'll conduct a question-and-answer session. Please be advised that this call is being recorded at the compnays request and a replay will be available on the company's website for one week from today.

I'll turn over the call to Jennifer Williams, Investor Relations for Omeros.

Jennifer Williams

Good afternoon and thank you for joining the call today. Dr. Greg Demopulos, Chairman and CEO of Omeros, will take you through a corporate update; and then Mike Jacobsen, our Chief Accounting Officer, will provide an overview of our fourth quarter financial results. We have some time reserved for questions after the financial overview.

I'd like to remind you that some of the statements that will be made on the call today will be forward-looking. These statements are based on management's beliefs and expectations as of today only and are subject to change. All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special note regarding forward-looking statements and the Risk Factors section in the company's quarterly report on Form 10-Q, which was filed today with the SEC for a discussion of these risks and uncertainties.

Recommended For You

Comments (10)

vitullijoe profile picture
is the offering done?
@vitullijoe no, it’s an ATM offering. Cantor can basically release shares at market price as they see fit to raise funds. They can take advantage of spikes without announcing a large formal offering at that time. They can also do it a little at a time over time. At least this is my understanding of it. I like this set up.
vitullijoe profile picture
Here is a link to the filing and prospectus. investor.omeros.com/... I think it is a great thing, CEO made the right call, this is big.
See no analyst asked about needing any additional capital and they issued a $150MM equity raise last night.
hwqin008 profile picture
@Hector22 you seems wrong. OMER has enough cash to funding, omidria run rate this year will be $180-$200millions.
@hwqin008 Then why are they are they trying raise $150MM if they don't need capital?
vitullijoe profile picture
So in the next 1/3 years why isn't OMER a10 t0 20 bagger?
hwqin008 profile picture
@vitullijoe 5 bagger at least
@vitullijoe It really depends on how it does in the I-SPY trial. But just accounting for the TMA patients after SCT, assuming it’s approved, it should be a 3x
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.